GLP-1 Treatment in Florida: What It Costs and Who Covers It
A Florida overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
29.6% of Florida adults have obesity and another 35.8% are overweight — together 65.4% of the 11,860 Florida respondents in the CDC's 2024 BRFSS cycle 1. The obesity figure has declined three cycles running: 31.6% (2022) → 30.1% (2023) → 29.6% (2024) 1.
It is also a falling rate inside a fast-growing denominator: Florida added 467,347 residents in the year ending July 1, 2024, reaching 23,372,215 2.
Florida Medicaid covers GLP-1 and dual GIP/GLP-1 receptor agonists only for type 2 diabetes — never for obesity or weight loss. Under AHCA's prior-authorization criteria (rev. March 12, 2026), Mounjaro, Ozempic, and Trulicity are "preferred" agents requiring clinical PA, with exenatide, liraglutide, and Rybelsus as non-preferred alternatives; every one of them requires a documented type 2 diabetes diagnosis, an HbA1c of 6.5% or higher within the past six months, and a metformin trial-and-failure within two years unless contraindicated. There is no obesity pathway anywhere in the document. Wegovy, Zepbound, and Saxenda do not appear in Florida's Preferred Drug List (eff. July 1, 2026) or its 123-page Summary of Drug Limitations (upd. July 31, 2026), and no dedicated prior-authorization document exists for any of the three in AHCA's full drug-criteria library — a library that names 400-plus other drugs and classes individually, which reads as confirmation of non-coverage rather than a gap. The one exception is Imcivree (setmelanotide), authorized solely for rare monogenic or syndromic obesity (POMC, PCSK1, or LEPR deficiency, or Bardet-Biedl syndrome, each confirmed by genetic testing) — not for common obesity. Florida is also one of 10 states that has not adopted ACA Medicaid expansion (KFF, current as of August 2026), narrowing Medicaid eligibility for low-income adults well before the drug-coverage question even applies.3
Does Florida Medicaid cover GLP-1s for weight loss?
No. Florida Medicaid covers GLP-1 and dual GIP/GLP-1 receptor agonists only for type 2 diabetes — never for obesity or weight loss. Under AHCA's prior-authorization criteria (rev. March 12, 2026), Mounjaro, Ozempic, and Trulicity are "preferred" agents requiring clinical PA, with exenatide, liraglutide, and Rybelsus as non-preferred alternatives; every one of them requires a documented type 2 diabetes diagnosis, an HbA1c of 6.5% or higher within the past six months, and a metformin trial-and-failure within two years unless contraindicated 3. There is no obesity pathway anywhere in the document.
Wegovy, Zepbound, and Saxenda do not appear in Florida's Preferred Drug List (eff. July 1, 2026) 4 or its 123-page Summary of Drug Limitations (upd. July 31, 2026) 5, and no dedicated prior-authorization document exists for any of the three in AHCA's full drug-criteria library 7 — a library that names 400-plus other drugs and classes individually, which reads as confirmation of non-coverage rather than a gap. The one exception is Imcivree (setmelanotide), authorized solely for rare monogenic or syndromic obesity (POMC, PCSK1, or LEPR deficiency, or Bardet-Biedl syndrome, each confirmed by genetic testing) — not for common obesity 6.
Florida is also one of 10 states that has not adopted ACA Medicaid expansion 8, narrowing Medicaid eligibility for low-income adults well before the drug-coverage question even applies. The statewide uninsured rate is 10.9% — 2,509,782 of 23,038,464 people in the insurance universe, per ACS 2024 1-year estimates 10.
What GLP-1 care costs in Florida
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
Median household income in Florida is $77,735 (ACS 2024 1-year estimate) 9. The price above is the same in Gainesville, Port St. Lucie, Tallahassee, and every other state Astra serves.
Telehealth prescribing rules in Florida
Astra's providers are licensed in Florida and follow all applicable state requirements. Prescriber licensing runs through the Florida Board of Medicine 11.
TODO — not verified in this research pass: Florida-specific telehealth prescribing rules for GLP-1s (in-person-exam requirements, any compounding-specific board guidance, statutory citations). This page states no Florida rule specifics until they are confirmed against Board of Medicine and Board of Osteopathic Medicine primary sources.
Getting treated in Florida
Astra treats patients in Florida and in all 50 states. Intake, prescription, and refills are handled online, with medication shipped from a state-licensed US compounding pharmacy.
Astra treats patients in Florida through state-licensed physicians.
GLP-1 care by city in Florida
City-level obesity, coverage, and local pricing detail for Gainesville, Port St. Lucie, and Tallahassee.
Does Florida Medicaid cover GLP-1 weight-loss drugs like Wegovy or Zepbound?
No. Florida Medicaid's GLP-1 prior-authorization criteria (AHCA, rev. March 12, 2026) cover Mounjaro, Ozempic, and Trulicity only for type 2 diabetes — there's no obesity or weight-loss pathway in the document, and Wegovy, Zepbound, and Saxenda aren't listed anywhere in the state's Preferred Drug List or Summary of Drug Limitations. The one narrow exception is Imcivree, for rare genetically-confirmed obesity syndromes, not common obesity.
Is Astra's price different in Florida than in other states?
No — Astra prices the same everywhere: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans ($816 and $1,416 paid annually). There's no Florida-specific rate, discount, or surcharge; it's the same price whether you're in Gainesville, Tallahassee, or any other state Astra serves.
Why doesn't Florida Medicaid cover GLP-1s for weight loss?
Florida's Medicaid pharmacy criteria simply don't include an obesity indication for any GLP-1 or dual GIP/GLP-1 drug — coverage is written for type 2 diabetes management only, with strict HbA1c and metformin-trial requirements. Florida is also one of 10 states that hasn't adopted ACA Medicaid expansion, which further limits how many low-income adults are Medicaid-eligible in the first place, regardless of the drug question.
What does GLP-1 treatment cost through Astra if I live in Florida?
Astra's Florida patients pay the same national rate as everyone else: $68/month for semaglutide or $118/month for tirzepatide, billed on a 12-month plan ($816 or $1,416 per year).
Does Astra treat patients throughout Florida, or only in certain cities?
Astra is licensed to treat patients across all of Florida — and in all 50 states — so where in the state you live doesn't affect whether you can get care. Florida city guides are available for Gainesville, Port St. Lucie, and Tallahassee, with local cost and access context for each.
Florida Medicaid Preferred Drug List (PDL), effective 07/01/2026 — Ozempic/Mounjaro listed under Antihyperglycemic classes, Clinical PA required; no Wegovy/Zepbound/Saxenda entries (not independently re-verified in fact-check pass — site returned 403) — https://ahca.myflorida.com/file/medicaid/PDL%20Effective%2007.01.2026.pdf